GlassScriptPhysician profile
Alfredo Gil
NPI 1982623153
$6,137.66
in general payments reported to CMS, 2019-2025
31 companies · $706 in 2025
The $706 reported for 2025 was more than what 87% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $947 · 2020: $704 · 2021: $1,213 · 2022: $1,105 · 2023: $754 · 2024: $708 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,982 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,982.15 |
| Education | $185.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $881.19 | 2019-2024 | |
| Astellas Pharma US INC | $872.87 | 2019-2025 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $618.28 | 2020-2025 | Slynd, Nuvessa |
| Agile Therapeutics, INC. | $533.46 | 2021-2023 | Twirla |
| Merz North America, INC. | $529.36 | 2019-2024 | |
| Mylan Pharmaceuticals INC. | $398.32 | 2019-2022 | |
| Therapeuticsmd, INC. | $369.99 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $367.77 | 2019-2025 | |
| Pfizer INC. | $176.09 | 2019-2023 | |
| Evofem Biosciences, INC. | $147.42 | 2020-2021 | |
| Avion Pharmaceuticals | $134.75 | 2019-2021 | |
| Sage Therapeutics, LLC | $134.68 | 2025 | Zurzuvae |
| Coopersurgical, INC. | $118.33 | 2019-2025 | Paragard T 380a |
| Mayne Pharma Commercial LLC | $101.67 | 2021-2023 | |
| Myriad Women'S Health, INC. | $81.02 | 2023 | Myrisk |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $78.80 | 2019-2020 | |
| Daiichi Sankyo INC. | $75.11 | 2019 | |
| Hologic Sales and Service, LLC | $74.64 | 2019-2023 | Aptima |
| Merck Sharp & Dohme LLC | $70.24 | 2019-2020 | |
| Shield Therapeutics INC | $57.96 | 2023-2025 | Accrufer |
| Organon LLC | $53.58 | 2022-2023 | Nexplanon |
| Exact Sciences Corporation | $45.74 | 2023 | Cologuard Collection Kit |
| Myovant Sciences INC. | $36.71 | 2021 | |
| Supernus Pharmaceuticals, INC. | $35.93 | 2025 | Qelbree |
| Hologic INC | $26.19 | 2021 | |
| Covidien LP | $25.92 | 2019 | |
| Galderma Laboratories, L.P. | $24.59 | 2020 | |
| Allergan, INC. | $20.96 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $16.21 | 2020 | |
| Alexion Pharmaceuticals, INC. | $16.00 | 2019 | |
| Boston Scientific Corporation | $13.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfredo Gil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.